Alejandro LÃ³pez-Soto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5439715/publications.pdf

Version: 2024-02-01

50 papers	3,792 citations	201674 27 h-index	223800 46 g-index
51 all docs	51 docs citations	51 times ranked	7136 citing authors

#	Article	IF	Citations
1	Carcinomaâ€“astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature, 2016, 533, 493-498.	27.8	677
2	Control of Metastasis by NK Cells. Cancer Cell, 2017, 32, 135-154.	16.8	549
3	The hallmarks of successful anticancer immunotherapy. Science Translational Medicine, 2018, 10, .	12.4	419
4	Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity, 2016, 44, 221-231.	14.3	279
5	NKG2D ligands: key targets of the immune response. Trends in Immunology, 2008, 29, 397-403.	6.8	218
6	WNT Signaling in Cancer Immunosurveillance. Trends in Cell Biology, 2019, 29, 44-65.	7.9	168
7	NKG2D signaling in cancer immunosurveillance. International Journal of Cancer, 2015, 136, 1741-1750.	5.1	109
8	HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene, 2009, 28, 2370-2382.	5.9	107
9	The NKG2D receptor: sensing stressed cells. Trends in Molecular Medicine, 2008, 14, 179-189.	6.7	103
10	Epithelialâ€“Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor. Journal of Immunology, 2013, 190, 4408-4419.	0.8	89
11	NK Cell-Based Immunotherapy in Cancer Metastasis. Cancers, 2019, 11, 29.	3.7	82
12	Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 1829-1836.	1.3	73
13	Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease. PLoS ONE, 2014, 9, e108326.	2.5	69
14	LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 2112.	3.7	62
15	Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer. International Journal of Molecular Sciences, 2020, 21, 3726.	4.1	61
16	Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor. Journal of Biological Chemistry, 2006, 281, 30419-30430.	3.4	54
17	NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. Cancer Research, 2018, 78, 3913-3925.	0.9	53
18	Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Frontiers in Immunology, 2014, 5, 106.	4.8	52

#	Article	IF	Citations
19	Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells. BioMed Research International, 2014, 2014, 1-11.	1.9	51
20	Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunology, Immunotherapy, 2012, 61, 1201-1210.	4.2	44
21	CD107a Degranulation Assay to Evaluate Immune Cell Antitumor Activity. Methods in Molecular Biology, 2019, 1884, 119-130.	0.9	43
22	Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors. OncoImmunology, 2016, 5, e1074378.	4.6	36
23	MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. Rheumatology, 2007, 46, 426-430.	1.9	35
24	Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. Frontiers in Immunology, 2018, 9, 2917.	4.8	35
25	Mechanisms of Resistance to NK Cell Immunotherapy. Cancers, 2020, 12, 893.	3.7	34
26	Immune and inflammatory responses to DNA damage in cancer and aging. Mechanisms of Ageing and Development, 2017, 165, 10-16.	4.6	32
27	MHC Class I Chain-Related Gene B Promoter Polymorphisms and Celiac Disease. Human Immunology, 2006, 67, 208-214.	2.4	29
28	Conceptual aspects of self and nonself discrimination. Self/nonself, 2011, 2, 19-25.	2.0	27
29	Involvement of autophagy in NK cell development and function. Autophagy, 2017, 13, 633-636.	9.1	27
30	BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 1766.	3.7	27
31	Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. OncoImmunology, 2017, 6, e1346766.	4.6	21
32	IFN Signaling and ICB Resistance: Time is on Tumorâ€™s Side. Trends in Cancer, 2017, 3, 161-163.	7.4	14
33	Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia. OncoImmunology, 2017, 6, e1353856.	4.6	14
34	Immunosurveillance of Malignant Cells with Complex Karyotypes. Trends in Cell Biology, 2017, 27, 880-884.	7.9	12
35	Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition. OncoImmunology, 2013, 2, e25820.	4.6	11
36	Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ÃŸ-D-Digitoxosyl-Mithramycin SK (EC-8042). PLoS ONE, 2015, 10, e0140786.	2.5	11

#	Article	IF	Citations
37	Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. Methods in Enzymology, 2020, 631, 483-495.	1.0	10
38	Immunosurveillance of cancer cell stress. Cell Stress, 2019, 3, 295-309.	3.2	10
39	A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells. Methods in Enzymology, 2020, 631, 343-355.	1.0	8
40	A Flow Cytometric NK Cell-Mediated Cytotoxicity Assay to Evaluate Anticancer Immune Responses In Vitro. Methods in Molecular Biology, 2019, 1884, 131-139.	0.9	6
41	Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers in Immunology, 2020, 11, 507.	4.8	5
42	Cancer-Induced Endoplasmic Reticulum Stress in T Cells Subverts Immunosurveillance. Cell Metabolism, 2018, 28, 803-805.	16.2	4
43	The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling. Frontiers in Immunology, 2019, 10, 2455.	4.8	4
44	Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. Bone Marrow Transplantation, 2020, 55, 461-463.	2.4	3
45	Biallelic IRF8 Mutations Causing NK Cell Deficiency. Trends in Molecular Medicine, 2017, 23, 195-197.	6.7	2
46	NK cell immune recognition. , 2010, , 65-77.		1
47	Papel de MICA en la patogenia de la artritis reumatoide. Seminarios De La Fundaciâˆšâ‰¥n EspaâˆšÂ±ola De Reumatologâˆšâ‰a, 2008, 9, 77-85.	0.1	0
48	Comment on â€œProteasome Regulation of ULBP1 Transcriptionâ€• Journal of Immunology, 2009, 183, 4145.1-4145.	0.8	0
49	The Molecular Basis of the Immune Response to Stressed Cells and Tissues. , 2016, , 53-79.		0
50	NKG2D Signaling: The Immune Subversive Side of HDAC3. Trends in Immunology, 2017, 38, 151-153.	6.8	0